GlassScriptPhysician profile
Dallas W Clark
NPI 1578234357
$12,430.75
in general payments reported to CMS, 2019-2025
45 companies · $2,224 in 2025
The $2,224 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $3,617 · 2023: $3,176 · 2024: $3,414 · 2025: $2,224.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,813.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,660.26 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Embecta Corp. | $852.90 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Abbott Laboratories | $815.50 | 2023-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $774.41 | 2022-2025 | Dexcom G6 Transmitter |
| Xeris Pharmaceuticals, INC. | $750.32 | 2022-2025 | Gvoke Hypopen, Recorlev |
| Sanofi-Aventis U.S. LLC | $696.75 | 2022-2024 | |
| Insulet Corporation | $657.35 | 2022-2024 | Omnipod |
| Horizon Therapeutics Plc | $646.96 | 2022-2023 | Tepezza |
| Lilly USA, LLC | $631.93 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Medtronic, INC. | $626.88 | 2023-2024 | Minimed 780g |
| Alexion Pharmaceuticals, INC. | $550.05 | 2022-2025 | Strensiq |
| Mannkind Corporation | $426.62 | 2024-2025 | |
| Abbvie INC. | $423.00 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $396.12 | 2022-2025 | |
| Amgen INC. | $298.38 | 2024-2025 | Evenity, Repatha, Tepezza |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $253.35 | 2022-2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.25 | 2022-2025 | Jardiance |
| Kyowa Kirin, INC. | $178.73 | 2024-2025 | Crysvita |
| Radius Health, INC. | $145.21 | 2024-2025 | Tymlos |
| Tandem Diabetes Care, INC. | $134.72 | 2022-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $134.61 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Bigfoot Biomedical INC | $128.38 | 2022 | |
| Almatica Pharma LLC | $99.83 | 2025 | Teriparatide |
| Neurocrine Biosciences, INC. | $83.04 | 2024-2025 | |
| Esperion Therapeutics, INC. | $80.55 | 2024-2025 | Nexletol |
| Lifescan, INC. | $74.38 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $72.94 | 2024-2025 | |
| Antares Pharma, INC. | $72.38 | 2022-2025 | Xyosted |
| Chiesi USA, INC. | $66.36 | 2025 | Mycapssa |
| Ascendis Pharma Endocrinology INC | $48.46 | 2025 | Yorvipath |
| Amryt Pharma Holdings LTD | $43.87 | 2022 | |
| Amneal Pharmaceuticals LLC | $42.59 | 2022-2025 | Unithroid |
| Intra-Sana Laboratories | $39.02 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Ibsa Pharma INC. | $38.18 | 2024-2025 | Licart, Tirosint, Flector |
| Pfizer INC. | $32.43 | 2025 | |
| Merck Sharp & Dohme LLC | $30.22 | 2025 | Zerbaxa |
| Ultragenyx Pharmaceutical INC. | $29.27 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $24.39 | 2025 | Airsupra |
| Glaxosmithkline, LLC. | $23.32 | 2025 | Shingrix, Arexvy |
| Tolmar, INC. | $21.33 | 2024 | |
| Recordati_rare_diseases_inc. | $21.26 | 2025 | Isturisa |
| Averitas Pharma INC. | $18.99 | 2025 | Qutenza |
| Aimmune Therapeutics, INC. | $16.44 | 2025 | Zenpep |
| Acella Pharmaceuticals, LLC | $16.43 | 2024 | NP Thyroid 60 |
| Shionogi INC | $15.39 | 2025 | Fetroja |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dallas Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.